Hepatitis B prevention, diagnosis, treatment and care: A review

Occupational Medicine

Volumn 61, Issue 8, 2011, Pages 531-540

  Aspinall, E J ^a   Hawkins, G ^a   Fraser, A ^b   Hutchinson, S J ^a,c   Goldberg, D ^a  

^a HEALTH PROTECTION SCOTLAND   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^c Department of Mathematics and Statistics ^*  (United Kingdom)

Author keywords

Hepatitis B; Hepatitis B vaccines; Occupational health

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B VACCINE;

DISEASE TRANSMISSION; FEMALE; HEPATITIS B; HUMAN; MALE; MASS SCREENING; METHODOLOGY; PREGNANCY; PREGNANCY COMPLICATION; REVIEW;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; MALE; MASS SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 82355195066     PISSN: 09627480     EISSN: 14718405     Source Type: Journal    
DOI: 10.1093/occmed/kqr136     Document Type: Review

References (54)

1. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995;13:S47-S49.
2. Salisbury D, Ramsay M, Noakes K. Immunisation Against Infectious Disease. London: Department of Health publication, 2006.
3. Kao HJ. Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev Gastroenterol Hepatol 2008;2:553-562.
4. Raimondo G, Pollicino T, Squadrito G. Clinical virology of hepatitis B virus infection. J Hepatol 2003;39:S26-S30.
5. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003;39:S64-S69.
6. Fattovich G. Natural history of hepatitis B. J Hepatol 2003;39:S50-S58.
7. World Health Organisation. Hepatitis B.WHO, 2002. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index.html (27 June 2011, date last accessed).
8. European Centre for Disease Prevention and Control. Hepatitis B and C in the EU Neighbourhood: Prevalence, Burden of Disease and Screening Policies. Stockholm, Sweden: ECDC, 2010.
9. Hahne S, Ramsay M, Balogun K et al. Incidence and routes of transmission of hepatitis B virus in England and Wales 1995-2000: implications for immunisation policy. J Clin Virol 2004;29:211-220.
10. Takkenberg RB, Weegink CJ, Zaaijer HL et al. New developments in antiviral therapy for chronic hepatitis B. Vox Sang 2010;98:481-494.
11. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009;29:S100-S107.
12. Raimondi S, Maisonneuve P, Bruno S et al. Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol 2010;52:441-449.
13. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis 2010;14:381-396.
14. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
15. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582-592.
16. Giacchino R, Cappelli B. Treatment of viral hepatitis B in children. Expert Opin Pharmacother 2010;11:889-903.
17. McMahon BJ, Holck P, Bulkow L et al. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759-768.
18. Cooke GS, Main J, Thursz MR. Treatment for hepatitis B. BMJ 2010;340:87-91.
19. Venook AP, Papandreou C, Furuse J et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010;15(Suppl. 4):5-13.
20. Chen JD, Yang HI, Iloeje UH et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010;138:1747-1754.
21. Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009;104:1693-1699.
22. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-696.
23. Jafri SMR, Lok ASF. Antiviral therapy for chronic hepatitis B. Clin Liver Dis 2010;14:425-438.
24. Di Marco V, Craxi A. Chronic hepatitis B: who to treat and which choice of treatment? Expert Rev Anti Infect Ther 2009;7:281-291.
25. Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2009;18:1655-1666.
26. National Institute for Health and Clinical Excellence. Telbivudine for the Treatment of Chronic Hepatitis B. NICE Technology Appraisal Guidance 154. London: NICE, 2008.
27. National Institute for Health and Clinical Excellence. Entecavir for the Treatment of Chronic Hepatitis B. NICE Technology Appraisal Guidance 153. London: NICE, 2008.
28. National Institute for Health and Clinical Excellence. Tenofovir Disoproxil for the Treatment of Chronic Hepatitis B. NICE Technology Appraisal Guidance 173. London: NICE, 2009.
29. Ter Borg MJ, Leemans WF, De Man RA et al. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008;15:37-41.
30. Lai M, Liaw YF. Chronic hepatitis B: past, present, and future. Clin Liver Dis 2010;14:531-546.
31. Shouval D. Hepatitis B vaccines. J Hepatol 2003; 39:S70-S76.
32. World Health Organisation. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec 2009;84:405-419.
33. Nguyen CT, Tran TT. Hepatitis vaccination and prophylaxis. Clin Liver Dis 2009;13:317-329.
34. Roome AJ, Walsh SJ, Cartter ML et al. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993;270:2931-2934.
35. Chen DS. Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol 2010;25:19-25.
36. Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis-United States, 2007. Surveillance Summaries. MMWR 2009;58(No. SS-3):1-27.
37. Namgyal P. Impact of hepatitis B vaccination, Europe and worldwide. J Hepatol 2003;39:S77-S82.
38. European Centre for Disease Prevention and Control. Surveillance and Prevention of Hepatitis B and C in Europe. Stockholm, Sweden: ECDC, 2010.
39. Australian Technical Advisory Group on Immunisation. The Australian ImmunisationHandbook 9th Edition. Canberra, Australia: Australian Government, 2008.
40. Centers for Disease Controland Prevention. Acomprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II. MMWR 2006;55(RR-16):1-33.
41. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001;50(No. RR-11):1-54.
42. Centers for Disease Controland Prevention. Acomprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1. MMWR 2005;54(RR-16):1-23.
43. Department of Health. Screening of Pregnant Women for Hepatitis B and Immunisation of Babies at Risk. Health Service Circular 1998/127. London: Department of Health, 1998.
44. Pruss-Ustun A, Rapiti E, Hutin Y. Global Burden of Disease from Sharps Injuries to Health-CareWorkers. Geneva, Switzerland: WHO, 2003.
45. Wilburn SQ, Eijkemans G. Preventing needlestick injuries among healthcare workers: a WHO-ICN collaboration. Int J Occup Environ Health 2004;10:451-456.
46. Lee R. Occupational transmission of bloodborne diseases to healthcare workers in developing countries: meeting the challenges. J Hosp Infect 2009;72:285-291.
47. Gunson RN, Shouval D, Roggendorf M et al. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCW): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol 2003;27:213-230.
48. Henderson DK, Dembry L, Fishman NO et al. SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus and/or human immunodeficiency virus. Infect Control Hosp Epidemiol 2010;31:204-230.
49. Expert Advisory Group on Aids and the Advisory Group on Hepatitis. Guidance for Clinical Health Care Workers: Protection Against Infection with Bloodborne Viruses. HSC 1998/063. London: Department of Health, 1998.
50. Health Service Circular (HSC) 2000/020. Hepatitis B Infected Health Care Workers. London: Department of Health, 2000.
51. Scottish Government. Health clearance for tuberculosis, hepatitis B, hepatitis C and HIV for new healthcare workers with direct clinical contact with patients. Edinburgh: Scottish Government, 2008.
52. Scottish Government. Public Health etc. (Scotland) Act 2008 (asp 5), Edinburgh.
53. UK Government. The Public Health (Control of Disease) Act 1984, London.
54. Weinbaum CM, Mast EE,Ward JW. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology 2009;49:S35-S44.